Cardiovascular Health, Lifestyle Factors, and Social Determinants Among Hispanic or Latino Adults in the United States.

Background: Among Hispanic/Latino subgroups residing in the US, disparities in cardiovascular health status remain largely uncharacterized.

Methods: This national study used the National Health Interview Survey to assess the burden of cardiometabolic risk factors (hypertension, hyperlipidemia, obesity, diabetes) and cardiovascular diseases (history of heart attack, coronary heart disease, angina, stroke) across Hispanic/Latino subgroups (Mexican, Cuban, Puerto Rican, Central/South American), and the extent to which differences are related to lifestyle factors (physical inactivity, smoking, and alcohol consumption) and/or social determinants of health (income, education, food security, and health insurance status).

Results: The weighted study population included 35,549,841 Hispanic/Latino adults (26,008 respondents).

Disparities of women's authorship in Colombia: A cross-sectional analysis.

Accepted manuscripts published in medical journals play a crucial role within the scientific community. Over the past few decades, there has been a gradual increase in the number of women entering the medical field. However, women remain underrepresented as first and last authors in medical journals.

Copy Number Variation in Asthma: An Integrative Review.

Asthma is a complex disease with varied clinical manifestations resulting from the interaction between environmental and genetic factors. While chronic airway inflammation and hyperresponsiveness are central features, the etiology of asthma is multifaceted, leading to a diversity of phenotypes and endotypes. Although most research into the genetics of asthma focused on the analysis of single nucleotide polymorphisms (SNPs), studies highlight the importance of structural variations, such as copy number variations (CNVs), in the inheritance of complex characteristics, but their role has not yet been fully elucidated in asthma.

Cardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy: A Meta-analysis of Randomized Placebo-Controlled Trials.

Background: Cardiac myosin inhibitors (CMI) have emerged as the first disease-specific, noninvasive therapy with promising results in patients with hypertrophic cardiomyopathy. However, its role in obstructive hypertrophic cardiomyopathy (oHCM) remains uncertain, especially in secondary endpoints of randomized controlled trials (RCTs).

Methods: We systematically searched PubMed, Embase, Web of Science, and Clinicaltrials.